Vaxcyte, Inc.
PCVX
Rank in Stocks
#2023
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Share Price
$66.75
Last synced: 2026-10-20
Market Cap
$10.24B
Change (1 day)
4.81%
Change (1 year)
57.60%
Country
US
Trade Vaxcyte, Inc. (PCVX)
Category
Healthcare
Stock price history for Vaxcyte, Inc. (PCVX)
Highest end of day price: $65.77 on 2026-10-01
Lowest end of day price: $32.16 on 2020-06-01
Lowest end of day price: $32.16 on 2020-06-01
Stock price history of Vaxcyte, Inc. from 2020 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 18.76% |
| 2025 | -48.18% |
| 2024 | 49.19% |
| 2023 | 30.50% |
| 2022 | 103.95% |
| 2021 | -26.14% |
| 2020 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $514.04 | 20.59% |
US
|
|
| $241.53 | 778.61% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $808.43 | 15.33% |
CH
|
|
| $875.26 | 4.85% |
NL
|
